Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Marketing Surveillance on the Use of Prazaxa® Capsules in Japanese Patients With Nonvalvular Atrial Fibrillation After the Availability of Idarucizumab

NCT03175198 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT03175198
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03175198 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Marketing Surveillance on the Use of Prazaxa® Capsules in Japanese Patients With Nonvalvular Atrial Fibrillation After the Availability of Idarucizumab
Lead sponsor
Boehringer Ingelheim
Phase
Observational
Overall status
Completed
Start date
July 5, 2017
Completion date
January 12, 2021
Enrollment
5,660 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atrial fibrillation